Biocare Expands Antibody Choices for Ventana Instruments

Enhancing the VP Echelon product line, Biocare is pleased to announce the addition of p40 mouse monoclonal, Arginase-1, and Uroplakin II to our menu of prediluted antibodies optimized for the Ventana® BenchMark® XT Immunohistochemistry Staining Systems. The mouse monoclonal antibody p40 [BC28] may have applications in cases where p63 is used. While p63 has proven […]

New p40 Mouse Monoclonal Antibody Available from Biocare Medical

Biocare Medical is proud to announce the availability of a new highly specific p40 mouse monoclonal antibody (IVD). Mouse monoclonal anti-p40 [BC28] demonstrated similar sensitivity and specificity as the rabbit polyclonal p40, staining 97% (65/67) of cases of lung squamous cell carcinoma (SqCC) and 0% (0/71) cases of lung adenocarcinoma (ADC), in an in-house study. […]

Biocare Medical launches a highly specific six antibody panel for differentiation of adenocarcinoma vs. squamous cell carcinoma of the lung

Biocare Medical is proud to announce the launch of the PulmoPanel™ Multiplex IHC to clearly differentiate between adenocarcinoma (LADC) and squamous cell carcinoma (SqCC) of the lung with 97% specificity and 93% sensitivity. This Multiplex IHC contains six antibodies (TTF-1, Napsin A, p63, TRIM29, Desmoglein 3 and CK5), and aids in the critical differentiation of […]

Thank You For Visiting Biocare Medical at NSH 2010!

Biocare Medical would like to thank you for making the 36th Annual National Society of Histotechnology in Seattle, Washington the most successful meeting by far! Over 40% more visitors than last year joined us for an interactive learning experience to find out about the latest IHC and Molecular Pathology technologies, techniques, and products. Over steaming […]

Biocare Medical Releases Multiplex IHC Tests to Differentiate Adenocarcinoma vs. Squamous Cell Carcinoma and Impact Therapeutic Decisions

Biocare’s Multiplex IHC Tests Biocare introduces the Lung Adeno-2™ and Lung Squamous-2™ Multiplex IHC tests which aid in the critical differentiation of NSCLC squamous cell carcinoma vs. adenocarcinoma(1) with 100% specificity for squamous cell carcinoma and 79% sensitivity for adenocarcinoma. This differentiation is a critical component in therapeutic decisions such as the use of VEGF […]

Email Cart